News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

The Impact of Chemotherapy-Induced Myelosuppression

EP. 1: Chemotherapy Use & Chemotherapy-Induced Myelosuppression

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

EP. 2: Management of Chemo-Induced Myelosuppression

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

EP. 3: Chemotherapy-Induced Myelosuppression & COVID-19

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

EP. 4: CDK4/6 Inhibitors and Myelopreservation

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

EP. 5: Analyses of CDK4/6 Inhibitors for Myelopreservation

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

EP. 6: Chemotherapy-Induced Myelosuppression in SCLC: CDK4/6 Inhibition

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

EP. 7: CDK4/6 Inhibitors for SCLC: Trials of Interest

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

EP. 8: CDK4/6 Inhibitors & Myelopreservation in Other Cancers

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

EP. 9: Reducing the Impact of Chemotherapy-Induced Myelosuppression

ByPaul Bunn, MD, University of Colorado Cancer Center,Gary H. Lyman, MD, MPH, FASCO, FRCP, University of Washington School of Medicine

September 16th 2020

Trending on OncLive

FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC

SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma

Five Under 5: Top Oncology Videos for the Week of 1/25